General MedicationsINJECTIONGeneric

IMURAN

AZATHIOPRINE SODIUM

Standard Dose

EQ 100MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

Max Dose

Refer to approved labeling

Primary Use

Review priority: STANDARD Marketing status: Discontinued

Summary

Approval overview IMURAN is listed in Drugs@FDA under application 017391 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient AZATHIOPRINE SODIUM Form and strength INJECTABLE;INJECTION - EQ 100MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor CASPER PHARMA LLC Submission history Latest submission status date: 2024-07-09 00:00:00.

Structured Monograph

Clinical summary

Approval overview IMURAN is listed in Drugs@FDA under application 017391 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient AZATHIOPRINE SODIUM Form and strength INJECTABLE;INJECTION - EQ 100MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor CASPER PHARMA LLC Submission history Latest submission status date: 2024-07-09 00:00:00. Submission type: SUPPL.

Monitoring

• Marketing status: Discontinued
• Review priority: STANDARD

Interaction Notes

No interaction notes stored yet.